Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage

被引:15
作者
Peskar, BM
Ehrlich, K
Peskar, BA
机构
[1] Ruhr Univ Bochum, Fac Med, Dept Expt Clin Med, D-44780 Bochum, Germany
[2] Graz Univ, Dept Clin & Expt Pharmacol, A-8010 Graz, Austria
关键词
sodium salicylate; cyclooxygenase-2; gastric mucosal damage; ischaemia-reperfusion; adaptive gastroprotection; nitric oxide (NO);
D O I
10.1016/S0014-2999(01)01524-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interactions of sodium salicylate and the selective cyclooxygenase-2 inhibitors N-{2-(cyclohexyloxy)-4-nitrophenyl}-methanesulfonamide (NS-398) and 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5II)-furanone (DFU), dexamethasone and the nitric oxide (NO) synthase inhibitor N-G-nitro-L-arginine methylester (L-NAME) were examined in ischaemia-reperfusion damage and adaptive protection in the rat stomach. Ischaemia-reperfusion damage was substantially aggravated by pretreatment with NS-398 (4 mg/kg), DFU (2 mg/kg), dexamethasone (1 mg/kg) or L-NAME (3 and 10 mg/kg). Salicylate (0.01-0.05 mg/kg) reversed the aggravating effect of NS-398, DFU and dexamethasone, while the effect of L-NAME was counteracted by L-arginine (twice 400 mg/kg) but not salicylate (0.05 or 10 mg/kg). Instillation of 20% ethanol prevented mucosal damage induced by 70% ethanol. This adaptive gastroprotection was abolished by pretreatment with NS-398 (1 mg/kg), DFU (0.2 mg/kg) or L-NAME (10 mg/kg). Salicylate (0.01-0.05 mg/kg) reversed the inhibition of protection by NS-398 and DFU, while the effect of L-NAME (10 mg/kg) was antagonized by L-arginine (100 mg/kg) but not salicylate (0.05 mg/kg). The precise mechanism of the functional antagonism between extremely low doses of salicylate and selective cyclooxygenase-2 inhibitors remains to be investigated. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 27 条
[21]  
PESKAR BM, 1999, BR J PHARM, V128
[22]   Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor [J].
Riendeau, D ;
Percival, MD ;
Boyce, S ;
Brideau, C ;
Charleson, S ;
Cromlish, W ;
Ethier, D ;
Evans, J ;
Falgueyret, JP ;
FordHutchinson, AW ;
Gordon, R ;
Greig, G ;
Gresser, M ;
Guay, J ;
Kargman, S ;
Leger, S ;
Mancini, JA ;
ONeill, G ;
Ouellet, M ;
Rodger, IW ;
Therien, M ;
Wang, Z ;
Webb, JK ;
Wong, E ;
Xu, L ;
Young, RN ;
Zamboni, R ;
Prasit, P ;
Chan, CC .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (01) :105-117
[23]   GASTRIC CYTOPROTECTION BY SODIUM-SALICYLATE [J].
ROBERT, A .
PROSTAGLANDINS, 1981, 21 :139-146
[24]   Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase stress-activated protein kinase activation [J].
Schwenger, P ;
Bellosta, P ;
Vietor, I ;
Basilico, C ;
Skolnik, EY ;
Vilcek, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :2869-2873
[25]   Tachykinin-induced increase in gastric mucosal resistance: Role of primary afferent neurons, CGRP, and NO [J].
Stroff, T ;
Plate, S ;
Ebrahim, JS ;
Ehrlich, KH ;
Respondek, M ;
Peskar, BM .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 271 (06) :G1017-G1027
[26]   ASPIRIN-LIKE DRUGS, ETHANOL-INDUCED RAT GASTRIC INJURY AND MUCOSAL EICOSANOID RELEASE [J].
TRAUTMANN, M ;
PESKAR, BM ;
PESKAR, BA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 201 (01) :53-58
[27]  
VANJAARSVELD H, 1994, RES COMMUN MOL PATH, V86, P287